MedTrace Logo

Combined Effects of Early Behavioral Intervention and Propranolol on ASD

NCT02428205 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-03-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to explore the effects of propranolol in combination with early intensive behavioral intervention on social interaction, and secondarily on language, anxiety, adaptive behaviors, and global function in children with autism in a double-blinded, placebo-controlled pilot trial.

Conditions

Interventions

DRUG

Propranolol

Participant will receive Propranolol prior to each EIBI session

DRUG

Placebo

Participant will receive placebo prior to each EIBI session

Sponsors & Collaborators

  • Autism Science Foundation

    collaborator OTHER

  • University of Missouri-Columbia

    lead OTHER

Principal Investigators

  • David Q Beversdorf, MD · University of Missouri-Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2022-11-01
Completion
2022-11-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02428205 on ClinicalTrials.gov